Assess whether to resubmit, meet, or pause the program from scientific-advice

SITUATION After a CMO 483 that maps to the NDA CMC module, scientific-advice briefing book is what CMC change-control owner can touch in a labeling team facing a boxed-warning debate. Pharma & Life Sciences will live with To resubmit, meet, versus Pause the program on this FDA Response and Labeling file.

DECISION CMC change-control owner in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. CMC change-control owner can defend To resubmit, meet, from scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend To resubmit, meet, from scientific-advice briefing book; Pause the program is what the extract actually supports after a CMO 483 that maps to the NDA CMC module. 3. A CMO 483 that maps to the NDA CMC module never reached the population in scientific-advice briefing book — reopen intake, do not close to resubmit, meet, or. 4. Two facts in scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module conflict for CMC change-control owner; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether scientific-advice briefing book supports the labeled claim CMC change-control owner would keep. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for CMC change-control owner.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module). The follow-on FDA Response and Labeling action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in scientific-advice briefing book, then the action for CMC change-control owner - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - What changes to resubmit, meet, or if a CMO 483 that maps to the NDA CMC module is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others